Frost & Sullivan’s  2015 Europe Technology Leadership Award

Frost & Sullivan’s 2015 Europe Technology Leadership Award in the Cardiovascular Information Systems Market

We are proud to announce Frost & Sullivan is awarding EBIT for the second time for SUITESTENSA, our Cardiovascular Information System Integration Platform.

EBIT 2015

16/11/2015
Genova, (Italy)

NOVEMBER 2015
2015 European Cardiovascular Information Systems Technology Leadership Award

We are proud to announce Frost & Sullivan is awarding EBIT for the second time for our Technically Advanced Cardiovascular Information System Integration Platform: SUITESTENSA.

Based on its recent analysis of the cardiovascular information system (CVIS) market, Frost & Sullivan recognises EBIT with the Frost & Sullivan’s 2015 European Technology Leadership Award in the Cardiovascular Information Systems, because of its technically advanced integration, user-friendly interface, and commitment to customer support.

Frost & Sullivan Acclaims SUITESTENSA, the EBIT’s Technically Advanced Cardiovascular

 

“Due to the integration of different reporting methods and images-all collected on a single cardiology patient folder - SUITESTENSA enhances multi-disciplinary health services and multi-territorial data sharing, simplifying information mobility and telemedicine challenges,” said Frost & Sullivan Research Analyst Michelle Reich,“moreover, its multi-platform architecture runs different operating systems and programming environments, while a cross-platform web application is accessible via various web browsers”.

See a selection of SUITESTENSA’s Frost and Sullivan Award Press Release

See a selection of SUITESTENSA’s Frost and Sullivan Award Press Release


See the dedicated Frost & Sullivan Best Practices Research on SUITESTENSA Software

See the dedicated Frost & Sullivan Best Practices Research on SUITESTENSA Software


Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information may refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.
This page uses cookies. Visiting this web site, you approve the use of cookies. For more information about the use of cookies in this web site, please click on “More information”. I agree More information